Binge Eating Disorder

Current Binge Eating Disorder News & Information

0

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for ... - The Providence Journal

LCS Therapeutics and Lucerne Biosciences to Commercialize ‘813 Patent for …
The Providence Journal
Patent ‘813 features claims that encompass the use of the amphetamine prodrug lisdexamfetamine dimesylate (l-lysine-d-amphetamine) alone, or in combination with other pharmacologic therapies, for the treatment of Binge Eating Disorder (BED) according …

and more …read more

bingeatingdisorder.com • December 26, 2014


Previous Post

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for ... - The Providence Journal

Next Post

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for ... - The Providence Journal